Akinetic mutism caused by HIV-associated progressive multifocal leukoencephalopathy was successfully treated with mefloquine: A serial multimodal MRI study

Internal Medicine

Volumn 51, Issue 2, 2012, Pages 205-209

  Naito, Kasane ^a,b   Ueno, Hiroki ^a   Sekine, Mayu ^a,c   Kanemitsu, Munekazu ^a   Ohshita, Tomohiko ^a,d   Nakamura, Takeshi ^a   Yamawaki, Takemori ^a   Matsumoto, Masayasu ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d Suiseikai Kajikawa Hospital   (Japan)

Author keywords

Apparent diffusion coefficient (ADC); Highly active anti retroviral therapy (HAART); Human immunodeficiency virus infection (HIV); Mefloquine; Progressive multifocal leukoencephalopathy (PML); Proton magnetic resonance spectroscopy ( 1H MRS)

Indexed keywords

CHOLINE; CREATINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MEFLOQUINE; N ACETYLASPARTIC ACID; VIRUS DNA; VIRUS RNA;

ADULT; AKINETIC MUTISM; APRAXIA; ARTICLE; ATTENTION DISTURBANCE; BRAIN DAMAGE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMMUNICATION DISORDER; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYSARTHRIA; FLUID ATTENUATED INVERSION RECOVERY IMAGING; HEMIPLEGIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JC VIRUS; LEUKOCYTE COUNT; MALE; MEMORY DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME POLYMERASE CHAIN REACTION; WHITE MATTER;

AKINETIC MUTISM; HIV INFECTIONS; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MEFLOQUINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84862919126     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6253     Document Type: Article

References (26)

1. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60: 3761-3765, 2009.
2. Antinori A, Cingolani A, Lorenzini P, et al. Italian Registry Investigative Neuro AIDS Study Group. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 9: 47-53, 2003.
3. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 17: 365-370, 2004.
4. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53: 1840-1849, 2009.
5. Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 82: 452-455, 2011.
6. Kishida S, Tanaka K. Mefloquine treatment in a patient suffering from progressive multifocal leukoencephalopathy after umbilical cord blood transplant. Intern Med 49: 2509-2513, 2010.
7. Kishida S, Tanaka K, Ajisawa A, et al. Annual report of the research committee on prion disease and slow virus infection, research on measures for intractable diseases health and labour sciences research grants, the Ministry of Health. Labour and Welfare of Japan, 2010: 125-132 (in Japanese).
8. Clinical Trials.gov [Internet]. Maryland: U.S. National Institutes of Health; c1993- [updated 2011 July 7; cited 2011 Jul 25]. Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML). Available from: http:// clinicaltrials.gov/ct2/show/NCT0074694.
9. Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73: 1551-1558, 2009.
10. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIVassociated progressive multifocal leukoencephalopathy. Clin Infect Dis 40: 738-744, 2005.
11. Thurnher MM, Post MJ, Rieger A, Kleibl-Popov C, Loewe C, Schindler E. Initial and follow-up MR imaging findings in AIDSrelated progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 22: 977-984, 2001.
12. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 9: 25-31, 2003.
13. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndromeassociated progressive multifocal leukoencephalopathy. Ann Neurol 44: 341-349, 1998.
14. Arbusow V, Strupp M, Pfister HW, Seelos KC, Bruckmann H, Brandt T. Contrast enhancement in progressive multifocal leukoencephalopathy: a predictive factor for long-term survival? J Neurol 247: 306-308, 2000.
15. Kuker W, Mader I, Nagele T, et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrastenhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 13: 819-826, 2006.
16. Mader I, Herrlinger U, Klose U, Schmidt F, Kuker W. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. Neuroradiology 45: 717-721, 2003.
17. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 46: 22-25, 2004.
18. Usiskin SI, Bainbridge A, Miller RF, Jager HR. Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. AJNR Am J Neuroradiol 28: 285-286, 2007.
19. Buckle C, Castillo M. Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience. AJNR Am J Neuroradiol 31: 1031-1035, 2010.
20. Nakano M, Ueda H, Li JY, Matsumoto M, Yanagihara T. Measurement of regional N-acetylaspartate after transient global ischemia in gerbils with and without ischemic tolerance: an index of neuronal survival. Ann Neurol 44: 334-340, 1998.
21. Iranzo A, Moreno A, Pujol J, et al. Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatry 66: 520-523, 1999.
22. Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48: 836-845, 1997.
23. Cuvinciuc V, Martin-Blondel G, Marchou B, et al. Proton MR Spectroscopy of progressive multifocal leukoencephalopathyimmune reconstitution inflammatory syndrome. Am J Neuroradiol 31: 69-70, 2010.
24. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta- 1b. J Neurol 248: 979-986, 2001.
25. Matsui N, Nakane S, Harada M, et al. Neuroradiological study of a possible progressive multifocal leukoencephalopathy using diffusion tensor imaging and proton magnetic resonance spectroscopy. Rinsho Shinkeigaku (Clin Neurol) 46: 555-560, 2006 (in Japanese, Abstract in English).
26. Dreha-Kulaczewski SF, Helms G, Dechent P, Hofer S, Gartner J, Frahm J. Serial proton MR spectroscopy and diffusion tensor imaging in infantile Balo's concentric sclerosis. Neuroradiology 51: 113-121, 2009.